Abstracts tagged "Inflammation and osteoclasts"

Abstract Number: 2906 • 2014 ACR/ARHP Annual Meeting
Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis
Shuang Liu¹, Takeshi Kiyoi², Shohei Watanabe³ and Kazutaka Maeyama¹, ¹Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, ²Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, ³Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan
Background/Purpose: In recent years, one widespread and potentially important Ca2+ channel, store-operated Ca2+-release-activated Ca2+ (CRAC) channel is raised in drug discovery for rheumatoid arthritis (RA).…
Abstract Number: 1829 • 2013 ACR/ARHP Annual Meeting
Carboxypeptidase B2 Down-Regulates Osteoclast Activation In Inflammation
Jason Jungsik Song¹, Sang-Won Lee¹, Yong-Beom Park¹, Soo Kon Lee², Lawrence Leung³ and William H. Robinson⁴, ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ³Division of Hematology, Stanford University School of Medicine, Stanford, CA, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Carboxypeptidase B2 (CPB2) is well established to play an anti-fibrinolytic role by removing C-terminal lysine residues from fibrin, thereby preventing its cleavage by plasmin.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].